ReviewThe Journal of veterinary medical science2017
An overview of the toxicology and toxicokinetics of fusarenon-X, a type B trichothecene mycotoxin.
Review in The Journal of veterinary medical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- "Edible plant-associated fungal endophytes as sources of bioactive specialized metabolites: antimicrobial and docking insights".Archives of microbiology · 2026Article
- Survey of trichothecene contamination in imported and domestically produced feed in Japan.Mycotoxin research · 2026Article
- Mycotoxins Occurrence in Herbs, Spices, Dietary Supplements, and Their Exposure Assessment.Toxins · 2025Review
- Health Problems with Mycotoxins in Cattle-A Review.Molecules (Basel, Switzerland) · 2025Review
- Simultaneous determination and occurrence assessment of 55 mycotoxins in tea and spices using liquid chromatography-high resolution mass spectrometry.Mycotoxin research · 2025Article
- Cross-sectional biomonitoring of urinary deoxynivalenol, T-2 and HT-2 toxins, and zearalenone in Japanese adults.Environmental health and preventive medicine · 2025Article
- Article
- Proinflammatory cytokines interleukin-18 and interleukin-6 mediate anorexia induction by trichothecene deoxynivalenol and its congeners.Frontiers in veterinary science · 2024Article
- Traditional Meat Products-A Mycotoxicological Review.Life (Basel, Switzerland) · 2023Review
- Bioinformatic Analysis of Secondary Metabolite Biosynthetic Potential in PathogenicJournal of fungi (Basel, Switzerland) · 2023Article
- Mycotoxins and Essential Oils-From a Meat Industry Hazard to a Possible Solution: A Brief Review.Foods (Basel, Switzerland) · 2022Review
- Recent Research onFoods (Basel, Switzerland) · 2022Review
- Combined Exposure to Multiple Mycotoxins: An Example of Using a Tiered Approach in a Mixture Risk Assessment.Toxins · 2022Article
- Determination of Multiple Mycotoxins and Their Natural Occurrence in Edible Vegetable Oils Using Liquid Chromatography-Tandem Mass Spectrometry.Foods (Basel, Switzerland) · 2021Article
- Article
- Article
- Secondary metabolites (SMs) ofRSC advances · 2018Review
- Fungal infections in animals: a patchwork of different situations.Medical mycology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusarenon-X (FX) is a type B trichothecene mycotoxin that is frequently observed along with deoxynivalenol (DON) and nivalenol (NIV) in agricultural commodities. This review aims to give an overview of the literature concerning the toxicology and toxicokinetics of FX. FX is primarily found in cereals grown in temperate regions, but it can also be found worldwide because of the global transport of products. The major toxicity of FX occurs through inhibition of protein synthesis, followed by the disruption of DNA synthesis. Moreover, FX has also been shown to induce apoptosis in in vitro and in vivo studies. The targets of FX are organs containing actively proliferating cells, such as the thymus, spleen, skin, small intestine, testes and bone marrow. FX causes immunosuppression, intestinal malabsorption, developmental toxicity and genotoxicity. In addition, sufficient evidence of carcinogenicity in experimental animals is currently lacking, and the International Agency for Research on Cancer (IARC) classifies it as a group 3 carcinogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.